Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Irenic Capital Announces Intent to Vote AGAINST Capricorn’s Proposed NewMed Merger and FOR All of Palliser’s Proposals at Upcoming General Meetings

NEW YORK–(BUSINESS WIRE)–Irenic Capital Management, L.P. (together with its affiliates, “Irenic” or “we”), which has an approximately 2.8% stake in Capricorn Energy plc (LSE: CNE.L) (“Capricorn” or the “Company”), today announced its intent to vote AGAINST the Company’s proposed merger with NewMed Energy Limited Partnership (“NewMed”) and FOR all of Palliser Capital Master Fund Limited’s (together with its affiliates, “Palliser”) proposals at the upcoming General Meetings of Shareholders (the “General Meetings”).

Adam Katz, Co-Founder and Chief Investment Officer of Irenic, commented:

Irenic appreciates the steps taken by Capricorn’s Board of Directors (the ‘Board’) to facilitate an orderly transition and reiterates our intent to vote FOR the Palliser nominees at the upcoming Requisitioned General Meeting. Moreover, we reiterate our intent to vote AGAINST the NewMed transaction whenever the reconstituted Board ultimately decides to hold this vote. Since last fall, Irenic has opposed Capricorn’s proposed merger with NewMed and has encouraged the Company’s Board to terminate the transaction in favor of initiating an objective and speedy review of value-maximizing alternatives.

Today, we encourage Capricorn’s reconstituted Board to immediately return the Company’s excess capital and near-term contingent consideration receipts to shareholders, reduce the firm’s excessive overhead and end speculative exploration spending, and quickly maximize the value of the Company’s Egypt assets (including its working capital balance). Irenic firmly believes such steps are the best path forward for Capricorn shareholders.”

About Irenic

Irenic Capital Management, L.P. is an investment management firm founded by Adam Katz and Andy Dodge. Based in New York City, Irenic works collaboratively with publicly traded companies to ensure operating activities, capital deployment and management incentives are all aligned to create value for the company and its owners. For more information about Irenic, please visit www.irenicmgmt.com.

Contacts

For Investors:

Irenic Capital Management

contact@irenicmgmt.com

For Media:

Longacre Square Partners

Greg Marose / Charlotte Kiaie, 646-386-0091

irenic@longacresquare.com

#FOLLOW US ON INSTAGRAM